Embryonic development is a multistep process involving activation and repression of many genes. Enhancer elements in the genome are known to contribute to tissue and cell-type specific regulation of gene expression during the cellular differentiation. Thus, their identification and further investigation is important in order to understand how cell fate is determined. Integration of gene expression data (e.g. microarray or RNA-seq) and results of chromatin immunoprecipitation (ChIP)-based genome-wide studies (ChIP-seq) allows large-scale identification of these regulatory regions. However, functional validation of cell-type specific enhancers requires further in vitro and in vivo experimental procedures. Here we describe how active enhancers can be identified and validated experimentally. This protocol provides a step-by-step workflow that includes: 1) identification of regulatory regions by ChIP-seq data analysis, 2) cloning and experimental validation of putative regulatory potential of the identified genomic sequences in a reporter assay, and 3) determination of enhancer activity in vivo by measuring enhancer RNA transcript level. The presented protocol is detailed enough to help anyone to set up this workflow in the lab. Importantly, the protocol can be easily adapted to and used in any cellular model system.
Introduction
Development of a multicellular organism requires precisely regulated expression of thousands of genes across developing tissues. Regulation of gene expression is accomplished in large part by enhancers. Enhancers are short non-coding DNA elements that can be bound with transcription factors (TFs) and act from a distance to activate transcription of a target gene 1 . Enhancers are generally cis-acting and most frequently found just upstream of the transcription start site (TSS), but recent studies also described examples where enhancers were found much further upstream, on the 3' of the gene or even within the introns and exons 2 .
There are hundreds of thousands of potential enhancers in the vertebrate genomes 1 . Recent methods based on chromatin immunoprecipitation (ChIP) provide high-throughput data of the whole genome that can be used for enhancer analysis [3] [4] [5] [6] [7] [8] [9] . Though data obtained by ChIP-seq experiments greatly increases the likelihood to identify cell and tissue-specific enhancers, it is important to keep in mind that detected binding sites do not necessarily identify direct DNA binding and/or functional enhancers. Thus, further functional analysis of newly identified enhancers is indispensable. In this work, we present a basic three-step process of putative active enhancer identification and validation. This includes: 1) selection of putative transcription factor binding sites by bioinformatics analysis of ChIP-seq data, 2) cloning and validation of these regulatory sequences in reporter constructs, and 3) measurement of enhancer RNA (eRNA).
Exposure of embryonic stem (ES) cells to retinoic acid (RA) is frequently used to promote neural differentiation of the pluripotent cells 10 . RA exerts its effects by binding to RA receptors (RARα, β, γ) and retinoid X receptors (RXRα, β, γ). RARs and RXRs in a form of heterodimer bind to DNA motifs called RA-response elements, that is typically arranged as direct repeats of AGGTCA sequence (called as half site) and regulate transcription. Ligand-treatment experiments allowed the identification of several retinoic acid regulated genes in ES cells . NOTE: The output files give us information about the total number of peaks, enrichment of the motifs, the percentage of the background, and the target sequences with motifs, etc. (Figure 1) . Typically several motifs are listed in order of their significance. 5. Remap the #1 ranked motif (NR half `AGGTCA`) (use the script: remap_motif.sh) NOTE: As the result, the script generates a .bed file that will show which ChIP-peaks are covering genomic regions that contain the canonical binding site of the transcription factor of interest. 6. Download and visualize results of the aligned RXR ChIP-seq reads (mm_ES_RXR_24h_ATRA.bam (also download the .bai)) and the AGGTCA motif occurrences (mm_ES_RXR_24h_ATRA_homerpeaks_motif1_mm10s_200_remaped_mbed.bed) by Integrative Genomics Viewer (IGV) 15 to identify putative RAR/RXR binding sites (Figure 2 and Figure 3 ).
NOTE:
Integration of various ChIP-seq data will help to more precisely predict good candidate enhancers 16, 17 . Recent studies revealed that active enhancers are typically enriched for P300 and correlate with H3K4me1 and H3K27ac, and are located in open chromatin regions, thereby displaying DNase-I hypersensitivity is also recommended [18] [19] [20] [21] . 7. Use the "Define a region of interest" in IGV 15 to obtain 200 -400 bp sequence of the selected genomic region and use these sequences for subsequent primer designs.
Reporter Assay
NOTE: The luciferin/luciferase system is used as a very sensitive reporter assay for transcriptional regulation. Depending on the enhancer activity luciferase enzyme is produced that will catalyze the oxidation of luciferin to oxyluciferin resulting in bioluminescense, which can be detected. As a first step, identified putative enhancer sequences should be subcloned into a reporter vector (e.g. TK-Luciferase
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, pGL3 or NanoLuc).
Primer Design
1. Design PCR primers for amplification of 200 -400 bp of putative enhancer regions by Primer3 (available here: http://bioinfo.ut.ee/ primer3/) 23 2. Copy-paste the genomic sequence from IGV that includes the putative binding site into Primer3 (see step 1.7). Set product size range to 250 -300 bp in Primer3. 3. Validate the PCR primers using the UCSC Genome Browser's In silico PCR tool (https://genome.ucsc.edu/cgi-bin/hgPcr) 24 NOTE: This protocol in a later step uses HindIII and BamHI restriction enzymes for cloning. Check whether the PCR amplified sequence as predicted by the UCSC In-silico PCR tool will contain AAGCTT or GGATCC restriction sites (e.g. http://nc2.neb.com/ NEBcutter2/). 4. Obtain the required primers from a commercial vendor.
PCR Amplification of Enhancer Sequence from Genomic DNA
1. Purify template genomic DNA from primary cells (e.g. primary embryonic fibroblasts). Use commercial kit for gDNA isolation and follow the manufacturer's instructions. NOTE: High quality of gDNA is essential for successful PCR amplification. Appropriate BAC clones can be used if PCR is not easy from gDNA. 2. Prepare 50 µl PCR reaction containing 100 ng gDNA, 5 µl 10x buffer, 3 µl MgSO 4 (25 mM), 5 µl dNTP (2 mM each), 1.5 µl Fwd primer (10 µM), 1.5 µl Rev primer (10 µM), 1 µl DNA polymerase NOTE: Use high-fidelity DNA polymerase with a low error rate for the PCR reactions. 3. Set the PCR cycle (2 min 95 °C, (20 sec 95 °C, 10 sec 58 -65 °C, 18 sec 70 °C) x25 repeat, 2 min 70 °C, forever 4 °C). Set annealing temperature with the consideration of the primer's predicted Tm values. 4. Purify the PCR product with a commercial PCR purification kit and follow the manufacturer's instructions. 5. Introduce the restriction sites for cloning by repeating the PCR with primers as used above, but adding overhangs on their 5' ends (e.g.
Fwd: 5'-ATATAAGCTTxxxxxxxxxxxxxxxxxxxx-3' (HindIII), Rev: 5'-TATAGGATCCxxxxxxxxxxxxxxxxxxxx-3' (BamHI)). 6. Run 5 µl of the PCR product on agarose gel to check for unspecific PCR products.
NOTE: If more bands are detected, run the entire PCR product and purify the appropriate band by a commercial gel extraction kit. per 1 ml of buffer just before use. Add 100 µl β-galactosidase substrate buffer to 80 µl cell lysate. 3. Incubate the reactions at 37 °C until a faint yellow color has developed. Read absorbance at OD 420 nm on a plate reader and export data. NOTE: The time varies depending on the transfection efficiency, usually no longer than 30 min.
8. Luciferase Assay 1. Prepare 50 ml luciferin substrate reagent: 15.1 mg D-luciferin salt, 82.7 mg ATP salt, 185 mg MgSO 4 •7H 2 O, add to 50 ml polypropylene tube, then add 1.5 ml 1 M HEPES buffer, 48.5 ml ATP free water, vortex, make sure all compounds dissolve completely. Keep 5 -10 ml aliquots at -80 °C. 2. Warm 5 ml luciferin substrate reagent to room temperature before starting. Pipette 100 µl substrate reagent to each well of the white plate containing the 40 µl of the cell lysate and measure the signal immediately using a luminescent counter machine. 3. Obtain activities from at least three independent experiments in triplicate transfections. 4. Calculate first the base normalized luciferase activity and base normalized β-galactosidase values for each well by subtracting the average values measured for non-transfected cells from each value measured. Then calculate the ratio of luciferase/β-galactosidase activity.
Representative Results
We used a pan-specific RXR antibody in order to identify genome-wide which RA-regulated genes have receptor enrichment in their close proximity. Bioinformatics analysis of RXR ChIP-seq data obtained from ES cells treated with retinoic acid revealed the enrichment of the nuclear receptor half site (AGGTCA) under the RXR occupied sites (Figure 1) . Using a bioinformatics algorithm we mapped back the motif search result for the half site to the RXR ChIP-seq data (Figure 2 ). This analysis helped us to accurately identify those ChIP peaks which were overlapping with canonical nuclear receptor binding sites. Visualization of these sites in IGV indicated enrichment of these transcription factors in the close proximity of Hoxa1, a previously characterized RAR/RXR target (Figure 2 and Figure 3) . We also identified a novel RA target gene, namely PRMT8
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. This latter region contains a direct repeat with no spacer nucleotides between the two half sites (AGGTCAAGGTCA) (Figure 3) . To functionally validate that the element identified for Hoxa1 can indeed bind RAR/RXR and regulated by RA we constructed TK-luciferase reporter vectors that contained ~300bp genomic region, including the identified elements. We also constructed vectors without the response element ( Figure 5 ). ES cells were transfected and luciferase activity was measured in the absence and presence of retinoic acid ( Figure 5) . Constructs containing the retinoic acid response element (RARE) did show increased luciferase signal intensity upon RA treatment, while the construct without the RARE was not inducible.
We also studied the retinoic acid-dependent activity of the Hoxa1 enhancer. To ascertain if the sense and anti-sense eRNA expression of the Hoxa1 RAR/RXR-bound enhancer correlate with the mRNA expression of the gene, we also measured the level of Hoxa1 mRNA (Figure 6) . These results confirmed that the enhancer activity is induced by short-term RA treatment (3 hr), thus confirming that the enhancer is likely involved in RA-dependent enhancer regulation. 
Discussion
In recent years, advances in sequencing technology have allowed large-scale predictions of enhancers in many cell types and tissues [7] [8] [9] . The workflow described above allows one to perform primary characterization of candidate enhancers chosen based on ChIP-seq data. The detailed steps and notes will help anyone to set up a routine enhancer validation in the lab.
The most critical step in the luciferase reporter assay is the transfection efficiency. It is recommended to include a GFP-construct in order to estimate the transfection efficiency in every experiment. Having fresh and good quality of plasmids can be critical and can significantly improve the transfection. The presented protocol can be adapted to any cellular model system. It is highly recommended to use the appropriate cell type for the characterization of tissue-specific enhancers. Thus, luciferase reporter assay requires that the cells chosen for the experiment should be
